Marketing Operations Intern jobs in United States
cer-icon
Apply on Employer Site
company-logo

Sarepta Therapeutics · 1 day ago

Marketing Operations Intern

Sarepta Therapeutics is a leader in genetic medicine, particularly in Duchenne muscular dystrophy, and is seeking a Marketing Operations Intern. This role involves supporting the Commercial Operations team by enhancing operational workflows, assisting with metrics and reporting, and collaborating with cross-functional partners.

BiotechnologyGeneticsHealth CareTherapeutics
check
Growth Opportunities
badNo H1Bnote

Responsibilities

Supporting and optimizing metrics for material review efficiencies and quarterly business review processes
Assisting with Marketing Operations in leading material review meetings and agenda management
Participating in cross functional projects that improve processes and system efficiencies related to Material Review
Supporting the material review process with review of review meeting notes and publishing with internal stakeholders
Observing and learning from related Commercial Operations functions, including Field Operations, the Design Team, Business Operations, PRC review, forecasting, and print/digital workflows

Qualification

Microsoft OfficeExcelBusiness process improvementInterpersonal communicationSolution-oriented mindsetCollaborationOrganizational skillsDetail oriented

Required

Bachelor's degree candidates who have completed at least their sophomore year and are pursuing a degree in Business, Marketing, or Communications
Detail oriented, task focused, and interested in business process improvement
Proficient in Microsoft Office, with strong Excel skills
Excellent interpersonal, written, and verbal communication abilities
Strong collaborator with a solution-oriented mindset
High attention to detail and strong organizational skills

Benefits

Sarepta Therapeutics offers a competitive compensation and benefit package.

Company

Sarepta Therapeutics

company-logo
Sarepta Therapeutics focuses on the discovery and development of precision genetic medicine to treat rare diseases.

Funding

Current Stage
Public Company
Total Funding
$2.88B
Key Investors
Michael Andrew ChambersPharmakon AdvisorsMidCap Financial
2025-12-11Post Ipo Debt· $291.4M
2025-08-21Post Ipo Equity
2025-08-21Post Ipo Debt· $602M

Leadership Team

leader-logo
Ian Estepan
Executive Vice President, Chief Financial Officer
linkedin
K
Kathy Behrens Wilsey
Director
linkedin
Company data provided by crunchbase